Podda Marta Giorgia, Schiavello Elisabetta, Clerici Carlo Alfredo, Luksch Roberto, Terenziani Monica, Ferrari Andrea, Casanova Michela, Spreafico Filippo, Meazza Cristina, Biassoni Veronica, Chiaravalli Stefano, Puma Nadia, Bergamaschi Luca, Gattuso Giovanna, Sironi Giovanna, Nigro Olga, Massimino Maura
Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
BMJ Support Palliat Care. 2024 Dec 19;14(e3):e2642-e2648. doi: 10.1136/bmjspcare-2021-003031.
Despite improvements in survival, cancer remains the leading cause of non-accidental death in children and adolescents, who risk receiving high-intensity end-of-life (HI-EOL) care.
To analyse treatments for relapses (particularly in the last weeks of life), assess their impact on the EOL, identify patients most likely to receive HI-EOL care and examine whether palliative care services can contain the intensity of EOL care.
This retrospective study involved patients treated at the paediatric oncology unit of the Istituto Nazionale Tumori in Milan who died between 2018 and 2020. The primary outcome was HI-EOL care, defined as: ≥1 session of intravenous chemotherapy <14 days before death; ≥1 hospitalisation in intensive care in the last 30 days of life and ≥1 emergency room admission in the last 30 days of life.
The study concerned 68 patients, and 17 had HI-EOL care. Patients given specific in-hospital treatments in the last 14 days of their life more frequently died in hospital. Those given aggressive EOL care were less likely to die at home or in the hospice. Patients with central nervous system (CNS) tumours were more likely to have treatments requiring hospitalisation, and to receive HI-EOL care.
These results underscore the importance of considering specific treatments at the EOL with caution. Treatments should be administered at home whenever possible.The early activation of palliative care, especially for fragile and complicated patients like those with CNS cancers, could help families cope with the many problems they face.
尽管生存率有所提高,但癌症仍是儿童和青少年非意外死亡的主要原因,他们面临接受高强度临终关怀(HI-EOL)的风险。
分析复发治疗(尤其是在生命的最后几周),评估其对临终的影响,确定最有可能接受HI-EOL护理的患者,并研究姑息治疗服务是否可以控制临终护理的强度。
这项回顾性研究涉及2018年至2020年间在米兰国家肿瘤研究所儿科肿瘤病房接受治疗并死亡的患者。主要结局是HI-EOL护理,定义为:死亡前<14天进行≥1次静脉化疗;生命的最后30天内≥1次入住重症监护病房以及生命的最后30天内≥1次急诊室就诊。
该研究涉及68例患者,其中17例接受了HI-EOL护理。在生命的最后14天接受特定院内治疗的患者更常在医院死亡。接受积极临终护理的患者在家中或临终关怀机构死亡的可能性较小。患有中枢神经系统(CNS)肿瘤的患者更有可能接受需要住院的治疗,并接受HI-EOL护理。
这些结果强调了谨慎考虑临终时特定治疗的重要性。应尽可能在家中进行治疗。尽早启动姑息治疗,尤其是对于像CNS癌症患者这样脆弱和复杂的患者,可以帮助家庭应对他们面临的诸多问题。